Investors
A MESSAGE FROM OUR CEO
”There are more than 400,000 newly diagnosed patients each year in the Western World of which a large fraction would benefit from treatment with resomelagon as a new effective and safe treatment option.
-
January 9, 2025 RegulatorySynAct Pharma AB resolves on a directed share issue to guarantors
-
January 9, 2025 RegulatorySynAct Pharma AB announces outcome of the rights issue
-
December 30, 2024 RegulatoryChange in number of shares and votes in SynAct Pharma AB
The interim report for Q3 2024 was published on October 30, 2024, at 07.30 CEST.